Telithromycin: the first of the ketolides

OBJECTIVE: To review the chemistry, spectrum of activity, pharmacology, clinical efficacy, and safety of telithromycin. DATA SOURCES: A MEDLINE search from 1966 to December 2000 was performed via OVID and PubMed using the following search terms: HMR 3647, HMR3647, Ketek, RU 66647, and telithromycin. An extensive review of retrieved literature, abstracts from international scientific conferences, and minutes from regulatory authority meetings was also performed. DATA EXTRACTION: Medicinal chemistry, in vitro, animal, and human trials were reviewed for information on the antimicrobial activity, clinical efficacy, pharmacology, and safety of telithromycin. DATA SYNTHESIS: Several chemical modifications to the macrolide structure have led to the development of telithromycin, the first ketolide antimicrobial that demonstrates improved activity against penicillin- and macrolide/azalide-resistant Streptococcus pneumoniae due to its unique binding to the ribosomal target site. Although telithromycin may be useful in the treatment of community-acquired respiratory tract infections due to its activity against common typical and atypical pathogens, questions concerning its reliable activity against Haemophilus influenzae need to be addressed. Telithromycin's pharmacokinetics permit once-daily dosing for abbreviated periods and good distribution into lung tissue and phagocytic cells. Clinical and bacteriologic cure rates have been similar to those of comparator agents in human efficacy trials; however, the incidence of adverse gastrointestinal events were generally higher with telithromycin patients. Like other macrolides and many newer fluoroquinolones, telithromycin's ability to prolong the QTc interval is a potential safety issue, especially in elderly patients with predisposing conditions or those who are concurrently receiving drugs that are substrates for CYP2D6 and 3A4. Liver function test elevations demonstrated during clinical trials, although not overtly severe, may warrant monitoring in some patients taking multiple hepatically metabolized/cleared agents. CONCLUSIONS: Telithromycin offers potential advantages over traditional macrolides/azalides for community-acquired respiratory tract infections caused by macrolide-resistant pathogens. Further studies are needed to elucidate its clinical efficacy against H. influenzae, potential drug interactions, and safety in various subpopulations.

This article has been cited by other articles:

				S. Bolesta and B. P. Roslund Elevated hepatic transaminases associated with telithromycin therapy: A case report and literature review Am. J. Health Syst. Pharm., January 1, 2008; 65(1): 37 - 41. [Abstract] [Full Text] [PDF]

				X. Perrot, N. Bernard, C. Vial, J. C. Antoine, H. Laurent, T. Vial, C. Confavreux, and S. Vukusic Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment Neurology, December 26, 2006; 67(12): 2256 - 2258. [Abstract] [Full Text] [PDF]

				T. Bogdanovich, B. Bozdogan, and P. C. Appelbaum Effect of Efflux on Telithromycin and Macrolide Susceptibility in Haemophilus influenzae Antimicrob. Agents Chemother., March 1, 2006; 50(3): 893 - 898. [Abstract] [Full Text] [PDF]

				S. Yamaguchi, Y. L. Zhao, M. Nadai, H. Yoshizumi, X. Cen, S. Torita, K. Takagi, K. Takagi, and T. Hasegawa Involvement of the Drug Transporters P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 in Telithromycin Transport Antimicrob. Agents Chemother., January 1, 2006; 50(1): 80 - 87. [Abstract] [Full Text] [PDF]

				M. Reed, G. C Wall, N. P Shah, J. M Heun, and G. A Hicklin Verapamil Toxicity Resulting from a Probable Interaction with Telithromycin Ann. Pharmacother., February 1, 2005; 39(2): 357 - 360. [Abstract] [Full Text] [PDF]

				D. Abbanat, G. Webb, B. Foleno, Y. Li, M. Macielag, D. Montenegro, E. Wira, and K. Bush In Vitro Activities of Novel 2-Fluoro-Naphthyridine-Containing Ketolides Antimicrob. Agents Chemother., January 1, 2005; 49(1): 309 - 315. [Abstract] [Full Text] [PDF]

				T. S. Peters Do Preclinical Testing Strategies Help Predict Human Hepatotoxic Potentials? Toxicol Pathol, January 1, 2005; 33(1): 146 - 154. [Abstract] [Full Text] [PDF]

				L. Kolilekas, G. K Anagnostopoulos, I. Lampaditis, and I. Eleftheriadis Potential Interaction Between Telithromycin and Warfarin Ann. Pharmacother., September 1, 2004; 38(9): 1424 - 1427. [Abstract] [Full Text] [PDF]

				D. A Goff Short-Duration Therapy for Respiratory Tract Infections Ann. Pharmacother., September 1, 2004; 38(9_suppl): S19 - S23. [Abstract] [Full Text] [PDF]

				R. Berisio, J. Harms, F. Schluenzen, R. Zarivach, H. A. S. Hansen, P. Fucini, and A. Yonath Structural Insight into the Antibiotic Action of Telithromycin against Resistant Mutants J. Bacteriol., July 15, 2003; 185(14): 4276 - 4279. [Abstract] [Full Text] [PDF]

				G. Ackermann and A. C. Rodloff Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide J. Antimicrob. Chemother., March 1, 2003; 51(3): 497 - 511. [Abstract] [Full Text] [PDF]